Nivolumab versus Cabozantinib: Comparing Overall Survival in Metastatic Renal Cell Carcinoma

Title
Nivolumab versus Cabozantinib: Comparing Overall Survival in Metastatic Renal Cell Carcinoma
Authors
Keywords
Curve fitting, Prognosis, Distribution curves, Meta-analysis, Renal cell carcinoma, Algorithms, Cancer detection and diagnosis, Cancer treatment
Journal
PLoS One
Volume 11, Issue 6, Pages e0155389
Publisher
Public Library of Science (PLoS)
Online
2016-06-07
DOI
10.1371/journal.pone.0155389

Ask authors/readers for more resources

Reprint

Contact the author

Publish scientific posters with Peeref

Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.

Learn More

Ask a Question. Answer a Question.

Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.

Get Started